Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/13/24 | Current report filing |
|
 |
9 | |
| 04/29/24 | Current report filing |
|
|
31 | |
| 04/25/24 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 04/24/24 | Statement of changes in beneficial ownership of securities |
|
2 | ||
| 04/01/24 | Annual report to security holders |
|
168 | ||
| 04/01/24 | Definitive proxy statements |
|
|
45 | |
| 03/20/24 | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
|
45 | |
| 03/11/24 | Annual report pursuant to Section 13 and 15(d) |
|
|
134 | |
| 02/29/24 | Current report filing |
|
|
9 | |
| 02/16/24 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
13 |